Article Details

Novartis to buy Clal Biotech portfolio co Cadent for $770m

Retrieved on: 2020-12-17 09:33:45

Tags for this article:

Click the tags to see associated articles and topics

Novartis to buy Clal Biotech portfolio co Cadent for $770m. View article details on hiswai:

Excerpt

Clal <b>Biotechnology</b> has a 13% stake in the US company, which is developing a portfolio of neuroscience and psychiatric drugs candidates.

Article found on: en.globes.co.il

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up